Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Morvarid Mohseni
SHP2 Inhibition Overcomes RTK-mediated Pathway Re-Activation in KRAS Mutant Tumors Treated With MEK Inhibitors
Molecular Cancer Therapeutics
Cancer Research
Oncology
Related publications
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
Cancer Discovery
Oncology
Combined MEK and BCL-XL Inhibition Kills KRAS -Mutant Cells
Cancer Discovery
Oncology
Shipping Out MEK Inhibitor Resistance With SHP2 Inhibitors
Cancer Discovery
Oncology
RAF Dimer Inhibition Enhances the Antitumor Activity of MEK Inhibitors in K‐RAS Mutant Tumors
Molecular Oncology
Cancer Research
Medicine
Oncology
Genetics
Molecular Medicine
Erratum: Mechanism of MEK Inhibition Determines Efficacy in Mutant KRAS- Versus BRAF-driven Cancers
Nature
Multidisciplinary
Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer
Cancer Letters
Cancer Research
Oncology
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Cancer Cell
Cancer Research
Oncology
Cell Biology
Allosteric Inhibitors Target KRAS in a Mutant-Specific Manner
Cancer Discovery
Oncology
Effective Use of PI3K and MEK Inhibitors to Treat Mutant Kras G12D and PIK3CA H1047R Murine Lung Cancers
Nature Medicine
Biochemistry
Medicine
Genetics
Molecular Biology